Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us.

Fredrik Joabsson, Chief Business Development Officer Tel. 070 776 17 37 ir@camurus.com. Om Camurus Camurus är ett svenskt forskningsbaserat läkemedelsföretag med fokus på utveckling och marknadsföring av differentierade och innovativa läkemedel för behandling av svåra och kroniska sjukdomar. Camurus ökar omsättningen och minskar förlusten Forskningsbaserade läkemedelsbolaget Camurus redovisar ökande omsättning under fjärde kvartalet jämfört med samma period året innan. Bolaget rapporterar minskad förlust. fredrik.tiberg@camurus.com . Fredrik Joabsson, Chief Business Development Officer Tel. 070 776 17 37 ir@camurus.com.

Camurus AB gick med förlust (2019) Camurus AB gick med förlust, -393 492 000 kr. Camurus AB ökade sin omsättning med 81,91% senaste räkenskapsåret. Bolaget har 70 … För mer information, se www.camurus.se. Ytterligare information Fredrik Tiberg, vd och koncernchef Tel. +46 46 286 46 92 fredrik.tiberg@camurus.com Rein Piir, VP Investor Relations Tel. +46 70 853 72 92 ir@camurus.com Denna information är sådan information som Camurus AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Camurus driver projekt både i egen regi och i partnerskap med internationella läkemedelsbolag. Bolaget har sitt säte i Lund. Kalender 2021-11-04: Kvartalsrapport 2021-Q3 2021-07-15 Lund - 14 april 2021 - Camurus AB (Nasdaq Stockholm; CAMX) meddelar idag att årsredovisningen för 2020 nu finns tillgänglig på bolagets hemsida, www.camurus.se.För Fredrik Joabsson Chief Business Development Officer Tel. +46 (0)70 776 17 37 ir@camurus.com About Buvidal Buvidal (buprenorphine prolonged-release solution for subcutaneous injection in prefilled syringe) is indicated for the treatment of opioid dependence within a framework of medical, social, and psychological treatment.

2021; 2021-04-14 Camurus årsredovisning för 2020; 2021-02-11 Camurus Bokslutskommuniké 2020; 2020; 2020-11-05 Camurus delårsrapport tredje kvartalet

"Camurus continued to deliver strong results in the fourth quarter with Camurus AB: Camurus' Full Year Report 2020 ir@camurus.com. Här samlar vi nyheter där bolaget Camurus nämns. är Nyemissionen Karriär, Produkter, Legal notice, Integritets policy, Kontakt, IR kontakt.

"Eu não vou poder ir - eu vou estar em Las Vegas no dia vinte e três. bolagen Oasmia respektive Camurus, som Läkemedelsvärlden tidigare rapporterat.

It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. Princeton, N.J. and Lund, Sweden — July 20, 2017 — Braeburn Pharmaceuticals (“Braeburn”) and Camurus (NASDAQ STO: CAMX) today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the companies’ weekly and monthly buprenorphine depots (CAM2038) to treat Opioid Use Disorder. Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive opinion recommending marketing authorization Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. About Camurus Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions.

Alla; IR/Årsredovisningar; Webb Jun 15, 2015 After a single dose of octreotide immediate release (IR) 200 µg, that has been developed using FluidCrystal® technology (Camurus AB, Lund Kund Camurus | Projekt Webbutveckling och produktion samt grafisk profil. Segment B2B | Marknad Ett spännande IR-projekt (Investor Relations).

Fredrik Tiberg vd och koncernchef. 046-286 46 92. ir@camurus.com. Camurus AB Ideon Science Park.
Hertz liten lastbil

horse riding and implantation
libresse scan
offert visma
bilia däck malmö
camilla persson benbow
grundtal drying rack
pandora aktiekurs

Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com

And when you're short on money, it Saving for retirement can be hard work, but the good news is that you can take advantage of tax-advantaged savings plans like an IRA. When you put money in a traditional IRA, you are not taxed on the invested amount. It can help you save mo Budgets Are Sexy "A personal finance blog that won't put you to sleep." - Benjamin Franklin .soapbox_disclosure_widget { all: initial; position: relative; float: right } .soapbox_disclosure_widget:hover #soapbox_disclosure_widget-details { Looking for a few basics on the history and mission of the nation's tax agency? An official website of the United States Government Looking for a few basics on the history and mission of the nation's tax agency?